News
| 22 March 2019 |
2018 Annual Report and Accounts and Notice of AGMLONDON, March 22, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, is pleased to confirm that a h… |
| 21 March 2019 |
Dr. Martin Edwards Joins Verona Pharma as Non-Executive DirectorLONDON, March 21, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that Dr. Martin… |
| 20 March 2019 |
PDMR DealingLONDON, March 20, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 18, 2… |
| 11 March 2019 |
PDMR DealingLONDON, March 11, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 8, 20… |
| 7 March 2019 |
PDMR DealingThe notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation. |
| 5 March 2019 |
PDMR DealingLONDON, March 05, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 4, 20… |
| 4 March 2019 |
Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPDSingle dose of ensifentrine DPI formulation produced statistically significant and clinically meaningful dose-dependent bronchodilator response and was well tolerated at all doses |
| 28 February 2019 |
Verona Pharma to Present at Cowen and Company 39th Annual Health Care ConferenceLONDON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announces that the Co… |
| 26 February 2019 |
Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development UpdateLONDON, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces its audited results for… |
| 20 February 2019 |
Verona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development UpdateLONDON, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will repo… |
Targeting unmet needs
384m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients
Read more about COPD and CF in the unmet needs section of this website
Basic & Clinical Pharmacology & Toxicology
Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD
The Lancet Respiratory Medicine
Peer-reviewed paper in the Lancet's highly-respected medication journal
Verona Pharma plc
3 More London Riverside,
London SE1 2RE
T: +44 (0)203 283 4200
E: info@veronapharma.com
© Verona Pharma plc 2019
